Current HSRC/RDRC Committee Roster
Vanderbilt
University Institutional Review Board
Human Subjects Radiation Committee - Radioactive Drug Research Committee
FDA Registration Number - RDRC013
The HSRC/RDRC Committee meets the second Friday of every month at 11:00AM. Meeting locations are subject to change. Please call the IRB office to confirm meeting location (322-2918).
Effective - October 1, 2006
| VOTING MEMBERS (5) | SPECIALTY |
|---|---|
| Chair - Ron Price, Ph.D. | Radiology and Radiological Sciences |
| Vice-Chair - Dominique Delbeke, M.D., Ph.D. | Nuclear Medicine |
| Bo Lu, M.D. | Radiation Oncology |
| Jeffrey Clanton, M.S., B.C.N.P. | Radiopharmacy |
| James Patton, Ph.D. | Radiology and Radiological Sciences |
| ALTERNATE MEMBERS | SPECIALTY |
|---|---|
| Randy Brill, M.D. | Radiology |
| Bapsi Chakravarthy, M.D. | Radiation Oncology |
| Reza Habibian, M.D. | Nuclear Medicine |
| Marni Gardner, D.Ph. | Nuclear Pharmacist |
| Martin Sandler | Nuclear Medicine |
Vanderbilt's Human Subjects Radiation Committee (HSRC) must approve all research proposals involving radiation exposure (x-rays or radionuclides) of human subjects from routine diagnostic or therapeutic procedures used in a supporting role, and which the subject would otherwise not receive as a part of his/her standard medical care. The HSRC application form and guidelines should be used for research projects that do not involve the use of "non-approved" radioactive drugs for pre-Phase 1 research. If you need help in completing an HSRC application and/or estimating the radiation dose, please contact the IRB to have the Radiaton Dose Calculation Member of the HSRC assist you.
For an application form, a list of radiation doses, or examples of risk statements, please go to the IRB Forms page.
Vanderbilt's Radioactive Drug Research Committee (RDRC) is authorized by the U.S. Food and Drug Administration (FDA) to approve research projects involving the use of certain "non-approved" radioactive drugs for pre-Phase 1 research which would otherwise require approval from the FDA in the form of an Investigational New Drug (IND). Use the RDRC application form and guidelines to submit proposals to the RDRC. If you need help in completing and RDRC application and/or estimating the radiation dose, contact the IRB to have the Radiation Dose Calculation Member of the RDRC assist you.
For an application form, a list of radiation doses, or examples of risk statements, please go to the IRB Forms page.